Emergent BioSolutions | EBS - Net Income


Emergent BioSolutions reported $-261.3M in Net Income for its fiscal quarter ending in June of 2023.





Net Income Change Date
Acadia Pharmaceuticals USD 3.64M 269.93M Mar/2026
Akebia Therapeutics USD -12.24M 12.78M Dec/2025
ALKERMES USD -66.48M 115.82M Mar/2026
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
Amarin USD -1.22M 6.51M Dec/2025
ANI Pharmaceuticals USD 29.49M 2.86M Mar/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Coherus Biosciences USD -37.64M 2.11M Dec/2025
Emergent BioSolutions USD -261.3M 78.3M Jun/2023
Exelixis USD 210.47M 34.06M Mar/2026
Glaxosmithkline GBP 846.06M 1.87B Dec/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -93M 136M Mar/2026
Ironwood Pharmaceuticals USD 3.19M 457K Dec/2024
Lexicon Pharmaceuticals USD -15.53M 2.76M Dec/2025
Lonza CHF 426M 119M Jun/2025
Merck USD -4.24B 7.2B Mar/2026
Moderna USD -1.34B 517M Mar/2026
Myriad Genetics USD -7.9M 19.5M Dec/2025
Nektar Therapeutics USD -36.08M 978K Dec/2025
Neurocrine Biosciences USD 197.9M 44.2M Mar/2026
Pacira USD 2.92M 1.28M Mar/2026
Pfizer USD 2.69B 4.34B Mar/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Sanofi EUR 1.61B 2.42B Mar/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
United Therapeutics USD 274.9M 89.4M Mar/2026
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024
Xoma USD -17.24M 33.23M Sep/2024